From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Drug-Resistant Avian Flu Virus Reported

The H5N1 avian flu virus has now spread from Asia to Europe. The virus is already a great threat to the world’s poultry industry, but the greater threat is that it will mutate, enabling easy infection and spread among humans. The only defenses against a new pandemic are immunization and antiviral treatment.

In vitro testing has shown that most H5N1 isolates are sensitive to the antiviral drug oseltamivir (Tamiflu). This has led many countries to stockpile the drug (for example, the U.K. has allocated funds to obtain enough to treat over 20% of its population). Flu viruses mutate readily, however, leading to concern that drug resistance could rapidly develop in an epidemic.

An international team reports that a 14-year-old Vietnamese girl infected with the H5N1 virus, and treated for 3 days with oseltamivir, developed resistance to the drug. Fortunately, the girl recovered. When ferrets were infected with the resistant virus, oseltamivir was ineffective. The oseltamivir-resistant strains of the virus were, however, easily killed by zanamivir (Relenza), in vitro and in the ferrets.

Comment: This report is discouraging, though not surprising. It calls into question the public-health value of investing in huge stockpiles of oseltamivir. Although the authors argue that their data suggest it might be useful to stockpile zanamivir, the data provide no reason to believe that resistance to that drug would not develop just as rapidly.

— Anthony L. Komaroff, MD

Published in Journal Watch General Medicine November 4, 2005

Citation(s):

Le QM et al. Isolation of drug-resistant H5N1 virus. Nature 2005 Oct 20; 437:1108.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2005. Massachusetts Medical Society. All rights reserved.